<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39325828</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.</ArticleTitle><Pagination><StartPage>e1004397</StartPage><MedlinePgn>e1004397</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1004397</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1004397</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination strategies adapted to Pacific Islanders singularities.</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">We evaluated the humoral immune response of 585 adults, self-declaring as Melanesians, Europeans, Polynesians, or belonging to other communities, to the Pfizer BNT162b2 vaccine. Anti-spike and anti-nucleoprotein IgG levels, and their capacity to neutralize SARS-CoV-2 variants and to mediate antibody-dependent cellular cytotoxicity (ADCC) were assessed across communities at 1 and 3 months post-second dose or 1 and 6 months post-third dose. All sera tested contained anti-spike antibodies and 61.3% contained anti-nucleoprotein antibodies, evidencing mostly a hybrid immunity resulting from vaccination and SARS-CoV-2 infection. At 1-month post-immunization, the 4 ethnic communities exhibited no significant differences in their anti-spike IgG levels (p value = 0.17, in an univariate linear regression model), in their capacity to mediate omicron neutralization (p value = 0.59 and 0.60, in an univariate logistic regression model at 1-month after the second and third dose, respectively) and in their capacity to mediate ADCC (p value = 0.069 in a multivariate linear regression model), regardless of the infection status. Anti-spike IgG levels and functionalities of the hybrid humoral immune response remained equivalent across the 4 ethnic communities during follow-up and at 6 months post-third dose.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study evidenced Pacific Islander's robust humoral immune response to Pfizer BNT162b2 vaccine, which is pivotal to re-enforce vaccination deployment in a population at risk for severe COVID-19.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This trial has been register in ClinicalTrials.gov (ID: NCT05135585).</AbstractText><CopyrightInformation>Copyright: © 2024 Inizan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inizan</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1933-1515</Identifier><AffiliationInfo><Affiliation>Dengue and Arboviroses - Research and Expertise Unit - Institut Pasteur in New Caledonia - Pasteur Network, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courtot</LastName><ForeName>Adrien</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Provincial Office for Health and Social Action of the South Province (Direction Provinciale de l'Action Sanitaire et Sociale en Province Sud), Nouméa, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturmach</LastName><ForeName>Chloé</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffon</LastName><ForeName>Anne-Fleur</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Dengue and Arboviroses - Research and Expertise Unit - Institut Pasteur in New Caledonia - Pasteur Network, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biron</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1756-7655</Identifier><AffiliationInfo><Affiliation>New Caledonia Territorial Hospital, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruel</LastName><ForeName>Timothée</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3952-4261</Identifier><AffiliationInfo><Affiliation>Antiviral Activities of Antibodies Group, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Research Institute, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Enouf</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaneuf</LastName><ForeName>Thibaut</ForeName><Initials>T</Initials><Identifier Source="ORCID">0009-0005-9181-5567</Identifier><AffiliationInfo><Affiliation>Social and Sanitary Agency of New Caledonia (Agence Sanitaire et Sociale de Nouvelle-Calédonie), Nouméa, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munier</LastName><ForeName>Sandie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwartz</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-0729-1475</Identifier><AffiliationInfo><Affiliation>Virus and Immunity Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vaccine Research Institute, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gourinat</LastName><ForeName>Ann-Claire</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>New Caledonia Territorial Hospital, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Médevielle</LastName><ForeName>Georges</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Provincial Office for Health and Social Action of the South Province (Direction Provinciale de l'Action Sanitaire et Sociale en Province Sud), Nouméa, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouan</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dengue and Arboviroses - Research and Expertise Unit - Institut Pasteur in New Caledonia - Pasteur Network, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Werf</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Reference Center for Respiratory Viruses, Institut Pasteur, Université Paris Cité, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Genetics of RNA Viruses Unit, Institut Pasteur, Université Paris Cité, CNRS UMR3569, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madec</LastName><ForeName>Yoann</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6201-1261</Identifier><AffiliationInfo><Affiliation>Epidemiology of Emerging Diseases, Institut Pasteur, Université de Paris, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albert-Dunais</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>New Caledonia Specialized Hospital, Nouméa, New Caledonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupont-Rouzeyrol</LastName><ForeName>Myrielle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6991-4893</Identifier><AffiliationInfo><Affiliation>Dengue and Arboviroses - Research and Expertise Unit - Institut Pasteur in New Caledonia - Pasteur Network, Dumbéa-sur-Mer, New Caledonia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05135585</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000920" MajorTopicYN="N">Antibody-Dependent Cell Cytotoxicity</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095188" MajorTopicYN="N">Pacific Island People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>11</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>19</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>13</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39325828</ArticleId><ArticleId IdType="pmc">PMC11466435</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1004397</ArticleId><ArticleId IdType="pii">PMEDICINE-D-24-01093</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tarantola A, Horwood PF, Goarant C, Bertrand S, Merilles OEA, Pedron T, et al.. Counting Oceanians of Non-European, Non-Asian Descent (ONENA) in the South Pacific to Make Them Count in Global Health. Trop Med Infect Dis. 2019;4. doi: 10.3390/tropicalmed4030114</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/tropicalmed4030114</ArticleId><ArticleId IdType="pmc">PMC6789437</ArticleId><ArticleId IdType="pubmed">31405081</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwood PF, Tarantola A, Goarant C, Matsui M, Klement E, Umezaki M, et al.. Health Challenges of the Pacific Region: Insights From History, Geography, Social Determinants, Genetics, and the Microbiome. Front Immunol. 2019;10. doi: 10.3389/fimmu.2019.02184</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02184</ArticleId><ArticleId IdType="pmc">PMC6753857</ArticleId><ArticleId IdType="pubmed">31572391</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrage RL, Mills KJ, Coyaso HC, Gronowski CK, Godinet MT. Community Resilience and Cultural Responses in Crisis: Lessons Learned from Pacific Islander Responses to the COVID-19 Pandemic in the USA. J Racial Ethn Health Disparities. 2024;11:560–573. doi: 10.1007/s40615-023-01541-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40615-023-01541-5</ArticleId><ArticleId IdType="pmc">PMC9970122</ArticleId><ArticleId IdType="pubmed">36849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385:1761–1773. doi: 10.1056/NEJMoa2110345</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>ISEE-NC. Institut de la statistique et des études économiques Nouvelle-Calédonie, Recensement. 2019.</Citation></Reference><Reference><Citation>DASS-NC. Direction des Affaires Sanitaires et Sociales de Nouvelle-Calédonie, Tableau de bord COVID-19. 2023.</Citation></Reference><Reference><Citation>Ochida N, Dupont-Rouzeyrol M, Moury PH, Demaneuf T, Gourinat AC, Mabon S, et al.. Evaluating the strategies to control SARS-CoV-2 Delta variant spread in New Caledonia, a zero-COVID country until September 2021. IJID Reg. 2023;8:64–70. doi: 10.1016/j.ijregi.2023.06.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijregi.2023.06.004</ArticleId><ArticleId IdType="pmc">PMC10423666</ArticleId><ArticleId IdType="pubmed">37583482</ArticleId></ArticleIdList></Reference><Reference><Citation>Secretariat of the Pacific Community, S. COVID-19 vaccination—Dataset—Pacific Data Hub. 2023.</Citation></Reference><Reference><Citation>Khalil L, Leary M, Rouphael N, Ofotokun I, Rebolledo PA, Wiley Z. Racial and Ethnic Diversity in SARS-CoV-2 Vaccine Clinical Trials Conducted in the United States. Vaccines (Basel). 2022;10. doi: 10.3390/vaccines10020290</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020290</ArticleId><ArticleId IdType="pmc">PMC8875029</ArticleId><ArticleId IdType="pubmed">35214748</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Priddy FH, Williams M, Carson S, Lavender B, Mathieson J, Frampton C, et al.. Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults. Vaccine. 2022;40:5050–5059. doi: 10.1016/j.vaccine.2022.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.07.009</ArticleId><ArticleId IdType="pmc">PMC9273612</ArticleId><ArticleId IdType="pubmed">35868948</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Kedzierski L, Chua BY, Mayo M, Lonzi C, Rigas V, et al.. Robust and prototypical immune responses toward COVID-19 vaccine in First Nations peoples are impacted by comorbidities. Nat Immunol. 2023;24:966–978. doi: 10.1038/s41590-023-01508-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01508-y</ArticleId><ArticleId IdType="pmc">PMC10232372</ArticleId><ArticleId IdType="pubmed">37248417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufloo J, Grzelak L, Staropoli I, Madec Y, Tondeur L, Anna F, et al.. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies. Cell Rep Med. 2021;2:100275. doi: 10.1016/j.xcrm.2021.100275</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100275</ArticleId><ArticleId IdType="pmc">PMC8057765</ArticleId><ArticleId IdType="pubmed">33899033</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Donis RO, Koup RA, Fong Y, Plotkin SA, Follmann D. A Covid-19 Milestone Attained—A Correlate of Protection for Vaccines. N Engl J Med. 2022;387:2203–2206. doi: 10.1056/NEJMp2211314</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp2211314</ArticleId><ArticleId IdType="pubmed">36507702</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Wang M, Zhang X, Li S, Lu Q, Zeng H, et al.. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients. Signal Transduct Target Ther. 2021;6:346. doi: 10.1038/s41392-021-00759-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00759-1</ArticleId><ArticleId IdType="pmc">PMC8463587</ArticleId><ArticleId IdType="pubmed">34561414</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al.. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12. doi: 10.1126/scitranslmed.abc3103</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abc3103</ArticleId><ArticleId IdType="pmc">PMC7665313</ArticleId><ArticleId IdType="pubmed">32817357</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, et al.. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. Viruses. 2020;12:513. doi: 10.3390/v12050513</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12050513</ArticleId><ArticleId IdType="pmc">PMC7291041</ArticleId><ArticleId IdType="pubmed">32384820</ArticleId></ArticleIdList></Reference><Reference><Citation>Huet K, White M, Griffon AF, Bloch E, Magnat E, Baudemont G, et al.. A seroprevalence study of SARS-CoV-2 and seasonal coronaviruses after the first SARS-CoV-2 circulation in New Caledonia, Pacific region. IJID Reg. 2024;11:100373. doi: 10.1016/j.ijregi.2024.100373</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijregi.2024.100373</ArticleId><ArticleId IdType="pmc">PMC11127231</ArticleId><ArticleId IdType="pubmed">38799796</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich D, Green RE, Kircher M, Krause J, Patterson N, Durand EY, et al.. Genetic history of an archaic hominin group from Denisova Cave in Siberia. Nature. 2010;468:1053–1060. doi: 10.1038/nature09710</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09710</ArticleId><ArticleId IdType="pmc">PMC4306417</ArticleId><ArticleId IdType="pubmed">21179161</ArticleId></ArticleIdList></Reference><Reference><Citation>Choin J, Mendoza-Revilla J, Arauna LR, Cuadros-Espinoza S, Cassar O, Larena M, et al.. Genomic insights into population history and biological adaptation in Oceania. Nature. 2021;592:583–589. doi: 10.1038/s41586-021-03236-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03236-5</ArticleId><ArticleId IdType="pubmed">33854233</ArticleId></ArticleIdList></Reference><Reference><Citation>Scepanovic P, Alanio C, Hammer C, Hodel F, Bergstedt J, Patin E, Thorball CW, et al.. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10:59. doi: 10.1186/s13073-018-0568-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-018-0568-8</ArticleId><ArticleId IdType="pmc">PMC6063007</ArticleId><ArticleId IdType="pubmed">30053915</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartle GE, Fryer HA, Gill PA, Boo I, Bornheimer SJ, Hogarth PM, et al.. Homologous but not heterologous COVID-19 vaccine booster elicits IgG4+ B-cells and enhanced Omicron subvariant binding. NPJ Vaccines. 2024;9:129. doi: 10.1038/s41541-024-00919-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00919-8</ArticleId><ArticleId IdType="pmc">PMC11252355</ArticleId><ArticleId IdType="pubmed">39013889</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al.. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol. 2022;7:eabn8014. doi: 10.1126/sciimmunol.abn8014</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abn8014</ArticleId><ArticleId IdType="pmc">PMC8939472</ArticleId><ArticleId IdType="pubmed">35076258</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al.. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023;23:556–567. doi: 10.1016/S1473-3099(22)00801-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Crotty S Hybrid immunity. Science. 2021;372:1392–1393.</Citation></Reference><Reference><Citation>Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, et al.. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28:1072–1082. doi: 10.1038/s41591-022-01721-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01721-6</ArticleId><ArticleId IdType="pmc">PMC9117148</ArticleId><ArticleId IdType="pubmed">35165453</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, et al.. Sex Differences in the Evolution of Neutralizing Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2021;224:983–988. doi: 10.1093/infdis/jiab127</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab127</ArticleId><ArticleId IdType="pmc">PMC7989436</ArticleId><ArticleId IdType="pubmed">33693749</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626–638. doi: 10.1038/nri.2016.90</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri.2016.90</ArticleId><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccine. 2008;26:3551–3555. doi: 10.1016/j.vaccine.2008.04.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.04.054</ArticleId><ArticleId IdType="pubmed">18524433</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunders MJ, Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020;53:487–495. doi: 10.1016/j.immuni.2020.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.08.003</ArticleId><ArticleId IdType="pmc">PMC7430299</ArticleId><ArticleId IdType="pubmed">32853545</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios-Pedrero M, Jansen JM, Blume C, Stanislawski N, Jonczyk R, Molle A, et al.. Signs of immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat Aging. 2022;2:896–905. doi: 10.1038/s43587-022-00292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-022-00292-y</ArticleId><ArticleId IdType="pmc">PMC10154205</ArticleId><ArticleId IdType="pubmed">37118289</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner JJ, Beck MA. The impact of obesity on the immune response to infection. Proc Nutr Soc. 2012;71:298–306. doi: 10.1017/S0029665112000158</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665112000158</ArticleId><ArticleId IdType="pmc">PMC4791086</ArticleId><ArticleId IdType="pubmed">22414338</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S, Chan YT, Revelo XS, Winer DA. The Immune Landscape of Visceral Adipose Tissue During Obesity and Aging. Front Endocrinol (Lausanne). 2020;11:267. doi: 10.3389/fendo.2020.00267</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00267</ArticleId><ArticleId IdType="pmc">PMC7243349</ArticleId><ArticleId IdType="pubmed">32499756</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaikh SR, Beck MA, Alwarawrah Y, MacIver NJ. Emerging mechanisms of obesity-associated immune dysfunction. Nat Rev Endocrinol. 2024;20:136–148. doi: 10.1038/s41574-023-00932-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-023-00932-2</ArticleId><ArticleId IdType="pubmed">38129700</ArticleId></ArticleIdList></Reference><Reference><Citation>de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71:332–338. doi: 10.1017/S0029665112000092</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0029665112000092</ArticleId><ArticleId IdType="pubmed">22429824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kara Z, Akçin R, Demir AN, Dinç H, Taşkın HE, Kocazeybek B, et al.. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Obes Surg. 2022;32:2987–2993. doi: 10.1007/s11695-022-06181-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11695-022-06181-y</ArticleId><ArticleId IdType="pmc">PMC9263798</ArticleId><ArticleId IdType="pubmed">35802279</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates JT, Farmer AP, Bierdeman MA, Ederer DR, Carney LS, Montgomery DD, et al.. IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity. Vaccines (Basel). 2022;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9025933</ArticleId><ArticleId IdType="pubmed">35455261</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasr MC, Geerling E, Pinto AK. Impact of Obesity on Vaccination to SARS-CoV-2. Front Endocrinol (Lausanne). 2022;13:898810. doi: 10.3389/fendo.2022.898810</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.898810</ArticleId><ArticleId IdType="pmc">PMC9252434</ArticleId><ArticleId IdType="pubmed">35795152</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: systematic review and meta-analysis. BMJ Nutr Prevention Health. 2022:e000375. doi: 10.1136/bmjnph-2021-000375</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjnph-2021-000375</ArticleId><ArticleId IdType="pmc">PMC8783972</ArticleId><ArticleId IdType="pubmed">35814718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>